Stocks Health care SANA
NASDAQ · Health careSana Biotechnology, Inc. (SANA)
It posted a net loss of $149.3M. In fiscal 2025 capital spending exceeded operating cash flow by $144.8M. At September 30, 2026 it held $41.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Sana Biotechnology, Inc.
- Net worth
- Sana Biotechnology, Inc. has a market value (market cap) of $737.9M at the latest share price, and shareholders' equity of $180.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $143.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sana Biotechnology, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Sana Biotechnology, Inc. does
Sana Biotechnology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SANA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$244.2M | -$0.96 | -$144.8M |
| 2024 | n/a | -$266.8M | -$1.16 | -$256.6M |
| 2023 | n/a | -$283.3M | -$1.46 | -$273.6M |
| 2022 | n/a | -$269.5M | -$1.43 | -$310.9M |
| 2021 | n/a | -$355.9M | -$2.14 | -$280.9M |
| 2021 | n/a | -$285.3M | -$21.92 | -$161.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Sana Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 10, 2026
- June 5, 2026
- May 21, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Other event 8-K
Insider trades
What the people running Sana Biotechnology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Bishop Hans EdgarDirector | Received as pay | 8,680 | - |
| August 27, 2026 | Patel Dhavalkumar DhirajlalEVP, Chief Scientific Officer | Shares withheld for tax | 41,158 | $169.2K |
| August 26, 2026 | Patel Dhavalkumar DhirajlalEVP, Chief Scientific Officer | Exercised options | 125,000 | - |
| July 6, 2026 | Bishop Hans EdgarDirector | Received as pay | 6,297 | - |
| April 6, 2026 | Bishop Hans EdgarDirector | Received as pay | 7,763 | - |
| March 9, 2026 | Wyrick Susan D.See Remarks | Shares withheld for tax | 3,342 | $10.5K |
| March 9, 2026 | Wyrick Susan D.See Remarks | Shares withheld for tax | 1,045 | $3.2K |
| March 9, 2026 | Harr StevePresident & CEO, Director | Shares withheld for tax | 11,526 | $36.1K |
Who owns SANA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| (S) Robert Nelsen13G, passive with 14 related filers | 20.6% | November 14, 2024 |
| Robert Nelsen13G, passive with 14 related filers | 15.4% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 12.5% | November 5, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.3% | May 21, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 211 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 37,429,515 | -769 |
| Flagship Pioneering, LLC | 25,001,856 | 0 |
| RA Capital Management, L.P. | 18,750,000 | new |
| BlackRock, Inc. | 16,675,173 | +2,434,998 |
| State Street Corp | 11,203,134 | +665,048 |
| Canada Pension Plan Investment Board | 10,218,400 | -3,500 |
| Vanguard Capital Management LLC | 8,375,421 | +940,697 |
| Bank of America Corp | 5,748,454 | +2,801,593 |
| Geode Capital Management, LLC | 4,677,959 | +495,986 |
| Marex Group Ltd | 3,989,100 | -10,000 |
| Marshall Wace, Llp | 2,931,436 | +2,266,979 |
| Alphabet Inc. | 2,812,500 | 0 |
| Goldman Sachs Group Inc | 2,367,935 | -813,180 |
| Integral Health Asset Management, LLC | 2,000,000 | -1,200,000 |
| Toronto Dominion Bank | 1,972,381 | new |
| Vanguard Portfolio Management LLC | 1,881,689 | +174,168 |
| Jacobs Levy Equity Management, Inc | 1,868,718 | new |
| Northern Trust Corp | 1,604,084 | +125,233 |
| Charles Schwab Investment Management Inc | 1,379,181 | +13,033 |
| Woodline Partners LP | 1,317,932 | 0 |
Insiders
4 insiders reported holding 14,187,279 shares in total, about $35M at the last price.
| Holder | Shares |
|---|---|
| Harr StevePresident & CEO, Director | 7,944,251 |
| Bishop Hans EdgarDirector | 5,863,480 |
| Wyrick Susan D.See Remarks | 196,196 |
| Patel Dhavalkumar DhirajlalEVP, Chief Scientific Officer | 183,352 |
Questions about SANA
What does Sana Biotechnology, Inc. do?
Sana Biotechnology, Inc. is a company in the Health care sector, listed on NASDAQ as SANA. Its shares trade on NASDAQ under the ticker SANA.
What is Sana Biotechnology, Inc.'s net worth?
Sana Biotechnology, Inc. has a market value (market cap) of $737.9M at the latest share price, and shareholders' equity of $180.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sana Biotechnology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $149.3M.
When did Sana Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Sana Biotechnology, Inc.'s next earnings report?
Sana Biotechnology, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SANA with
Follow SANA
Get an email when Sana Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sana Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.